Discussion highlights the uncertainty regarding acceptance of Elsevier's negotiation with Jisc.
So I came across this tweet from Laurent Gatto, who's head of the Computational Proteomics Unit at the University of Cambridge, UK: https://twitter.com/lgatt0/status/802189887860592640 My immediate reaction was not to retweet. Why? Because I am not comfortable recommending rejection (or acceptance!) of something I've not seen.
No takes yet. Share an insight, caveat, or question.
Mike Taylor (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: